News from trillium therapeutics inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 06, 2012, 07:00 ET

Trillium's anti-CD47 oncology program highlighted in prestigious journal

TORONTO, Sept. 6, 2012 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative and proprietary...

Apr 04, 2012, 13:00 ET

Trillium provides update on anti-CD47 cancer program

TORONTO, April 4, 2012 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and...

Mar 28, 2012, 07:00 ET

First Patient Treated in Trillium's Interstitial Cystitis/Bladder Pain Syndrome Clinical Trial

TORONTO, March 28, 2012 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and...

Dec 15, 2011, 07:00 ET

Trillium to Commence Clinical Testing of TTI-1612 in Patients with Interstitial Cystitis/Bladder Pain Syndrome

TORONTO, Dec. 15, 2011 /PRNewswire/ -Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and innovative...

May 12, 2011, 07:00 ET

Trillium raises funds to advance urology program into clinical trials

A new and innovative approach to the treatment of interstitial cystitis TORONTO, May 12 /PRNewswire/ - Trillium Therapeutics Inc., a...

Dec 02, 2010, 11:00 ET

Trillium's Cancer Stem Cell Program to be Highlighted at ASH

TORONTO, Dec. 2 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today...

Mar 11, 2010, 07:00 ET

Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs

TORONTO, March 11 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today...

Jan 28, 2010, 07:00 ET

Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors

TORONTO, Jan. 28 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today...

Jan 12, 2010, 10:00 ET

Trillium and Biogen Idec enter into global license agreement

TORONTO, Jan. 12 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today...

Nov 05, 2008, 07:30 ET

Trillium Strengthens its Board of Directors

TORONTO, Nov. 5 /PRNewswire/ - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry veterans...

Dec 19, 2006, 00:00 ET

Trillium's TTI-1612 product receives orphan drug designation in Europe and the United States

TORONTO, Dec. 19 /PRNewswire/ - Trillium Therapeutics Inc. (Trillium) today announced that its gastrointestinal product, TTI-1612, has been...

Oct 06, 2005, 01:00 ET

Trillium acquires Arthron Ltd.

TORONTO, Oct. 6 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical company, today announced that it has acquired all...

Dec 14, 2004, 00:00 ET

Trillium and Genentech enter into global license agreement

TORONTO, Dec. 14 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical company, announced today that it has entered into...

Jun 08, 2004, 01:00 ET

Professor Marc Feldmann Joins Trillium Therapeutics' Scientific Advisory Board

TORONTO, June 8 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) today announced that Dr. Marc Feldmann, a Professor at Imperial College London...

Jun 02, 2004, 01:00 ET

Trillium Adds Major Cytokine Receptor Antagonist Program

TORONTO, June 2 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) today announced that it has licensed exclusive worldwide rights to a series of...

Feb 23, 2004, 00:00 ET

Trillium Therapeutics Welcomes Dr. Michael Moore to Board of Directors

TORONTO, Feb. 23 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) announced today that Dr. Michael Moore, Chief Executive Officer of PIramed, has...

Feb 05, 2004, 00:00 ET

Trillium Therapeutics Raises an Additional $6.0 Million to Close Series A Round at $13.5 million

TORONTO, Feb. 5 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) announced today that the Company has raised an additional $6 million, bringing the...